Cancer immunotherapy: Immune checkpoint inhibitors
- Submission status
- Open
The idea of using the body’s immune system to destroy cancer cells has been around since the early days of oncology, but it is only in the last decade that immune checkpoint inhibitors have truly revolutionized cancer immunotherapy. Their development has opened up new treatment paradigms such as the concept of using a drug according to the carcinogenic mechanism rather than the tumor site, as in the case of anti-PD1 treatments in cancers linked to mismatch repair. Great potential remains in developing this treatment modality, combining drugs in new treatment regimens, and identifying biomarkers that might predict immune checkpoint inhibitor efficacy. In this collection, we will showcase recent developments in the field and illustrate how some of the next challenges can be addressed.
Editors
-
Professor Marc Tischkowitz, MD, PhD
University of Cambridge, United Kingdom
